Education
About Us
Working with TipRanks
Follow Us
Towa Pharmaceutical Co Ltd (TWAPF)
OTHER OTC:TWAPF
RESEARCH TOOLSreports
Total Valuation
Towa Pharmaceutical Co has a market cap or net worth of $1.01B. The enterprise value is $242.08B.
Market Cap$1.01B
Enterprise Value$242.08B
Share Statistics
Towa Pharmaceutical Co has 51,516,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,516,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Towa Pharmaceutical Co’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 4.12%.
Return on Equity (ROE)0.11
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)4.12%
Return on Capital Employed (ROCE)0.06
Revenue Per Employee56.58M
Profits Per Employee4.14M
Employee Count4,588
Asset Turnover0.55
Inventory Turnover1.52
Valuation Ratios
The current PE Ratio of Towa Pharmaceutical Co is 6.95. Towa Pharmaceutical Co’s PEG ratio is -0.49.
PE Ratio6.95
PS Ratio0.00
PB Ratio0.68
Price to Fair Value0.77
Price to FCF-3.34
Price to Operating Cash Flow36.66
PEG Ratio-0.49
Income Statement
In the last 12 months, Towa Pharmaceutical Co had revenue of 259.59B and earned 18.99B in profits. Earnings per share was 385.70.
Revenue259.59B
Gross Profit94.73B
Operating Income23.24B
Pretax Income26.33B
Net Income18.99B
EBITDA48.05B
Earnings Per Share (EPS)385.70
Cash Flow
In the last 12 months, operating cash flow was 23.40B and capital expenditures -28.74B, giving a free cash flow of -5.33B billion.
Operating Cash Flow23.40B
Free Cash Flow-5.33B
Free Cash Flow per Share-103.56
Dividends & Yields
Towa Pharmaceutical Co pays an annual dividend of $0.275, resulting in a dividend yield of 0.01%
Dividend Per Share$0.275
Dividend Yield0.01%
Payout Ratio26.12%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.35
52-Week Price Change38.49%
50-Day Moving Average18.87
200-Day Moving Average19.28
Relative Strength Index (RSI)98.45
Average Volume (3m)6.00
Important Dates
Towa Pharmaceutical Co upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 15, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend DateMar 28, 2025
Financial Position
Towa Pharmaceutical Co as a current ratio of 2.81, with Debt / Equity ratio of 126.42%
Current Ratio2.81
Quick Ratio1.58
Debt to Market Cap1.66
Net Debt to EBITDA3.86
Interest Coverage Ratio14.29
Taxes
In the past 12 months, Towa Pharmaceutical Co has paid 7.34B in taxes.
Income Tax7.34B
Effective Tax Rate0.28
Enterprise Valuation
Towa Pharmaceutical Co EV to EBITDA ratio is 6.60, with an EV/FCF ratio of -59.49.
EV to Sales1.22
EV to EBITDA6.60
EV to Free Cash Flow-59.49
EV to Operating Cash Flow13.56
Balance Sheet
Towa Pharmaceutical Co has $45.47B in cash and marketable securities with ¥230.98B in debt, giving a net cash position of $185.51B billion.
Cash & Marketable Securities$45.47B
Total Debt¥230.98B
Net Cash$185.51B
Net Cash Per Share$3.60K
Tangible Book Value Per Share$2.56K
Margins
Gross margin is 34.81%, with operating margin of 8.95%, and net profit margin of 7.31%.
Gross Margin34.81%
Operating Margin8.95%
Pretax Margin10.14%
Net Profit Margin7.31%
EBITDA Margin18.51%
EBIT Margin10.77%
Analyst Forecast
The average price target for Towa Pharmaceutical Co is $25.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$25.50
Price Target Upside0.67% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―